BioPharma Resources

Drug Trial Radar · NCT07234032

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

344

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Jan 22, 2031

Study completion Jan 22, 2031

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).

Conditions

  • Pulmonary Hypertension
  • Interstitial Lung Disease

Interventions

  • Treprostinil Palmitil Inhalation PowderDrug

    Oral inhalation using a capsule-based dry powder.

  • PlaceboDrug

    Oral inhalation in initial double-dummy titration period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 108 weeks

Locations

12 sites in 8 countries. Site status is shown where the registry gives one.

  • USA006

    Naples, Florida · Recruiting

  • USA003

    Bend, Oregon · Recruiting

  • CZE001

    Prague, Czechia · Recruiting

  • FRA003

    Le Kremlin-Bicêtre, France · Recruiting

  • GEO003

    Tbilisi, Georgia · Recruiting

  • DEU010

    Gauting, Germany · Recruiting

  • DEU006

    München, Germany · Recruiting

  • JPN007

    Yokohama, Japan · Recruiting

  • JPN004

    Narita, Chiba, Japan · Recruiting

  • KOR001

    Seoul, South Korea · Recruiting

  • ESP006

    Madrid, Spain · Recruiting

  • ESP003

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.